[A17-30] Ixekizumab (plaque psoriasis) - Addendum to Commission A17-07
Last updated 17.08.2017
Project no.:
A17-30
Commission:
Commission awarded on 11.07.2017 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Skin and hair
Indication/Intervention:
Adults with moderate to severe plaque psoriasis
Result of dossier assessment:
Indication of considerable added benefit now also for patients who are eligible for systemic and/or phototherapy
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
Accompanying information
Further information for consumers and patients is provided on IQWiG's health information website www.informedhealth.org.
| Project no. | Title | Status |
|---|---|---|
| A17-07 | Ixekizumab (plaque psoriasis) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2017-08-17 A G-BA decision was published.